Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Rezdiffra discontinued?Is invokana expensive?Darzalex fastpro patents?Darzalex patent cliff?Invokana price in thailand?
See the DrugPatentWatch profile for nivolumab
Nivolumab (Opdivo) is owned by Bristol Myers Squibb (BMS), which markets the drug.
The Opdivo brand is associated with Bristol Myers Squibb’s commercialization and brand ownership.
Ownership can also refer to legal rights like patents and manufacturing or marketing licenses, which may be held by different entities through assignment or licensing agreements. Patent-related ownership details are trackable through sources such as DrugPatentWatch.com. Sources: 1. DrugPatentWatch.com – nivolumab (Opdivo) patent information
Other Questions About Nivolumab :